Navigation Links
Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
Date:7/14/2008

- Company to Host Conference Call to Update Clinical Program -

CALGARY, July 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has now enrolled and treated 200 cancer patients in clinical studies with REOLYSIN(R), its proprietary formulation of the human reovirus.

"The clinical program has gained substantial momentum in the past year, culminating in the treatment of our 200th patient this week," said Dr. Brad Thompson, President and CEO of Oncolytics. "REOLYSIN(R) has been well tolerated by the patients, and has demonstrated activity in all trials reported on to date. Our current studies will allow us to design our pivotal program based on Phase II data from human clinical studies."

Together with its collaborators, Oncolytics is now recruiting or enrolling patients in ten Phase I/II or Phase II clinical trials with REOLYSIN(R) in the U.S. and the U.K., and has permission to begin another Phase II trial in the U.S. These trials include four monotherapy trials using REOLYSIN(R) alone, and seven trials using REOLYSIN(R) in combination with radiation or chemotherapy.

Conference Call Details

Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call on Wednesday, July 16, 2008 at 11:30 a.m. MST (1:30 p.m. EST) to update investors on the Company's current and future clinical program for REOLYSIN(R).

To access the conference call by telephone, dial 1-416-644-3414 or 1-800-733-7571. A live audio webcast will be available through the Company's website at http://www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at http://www.oncolyticsbiotech.com and will also be available by teleph
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
2. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
3. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
5. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
6. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
7. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
8. Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)
9. Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
10. Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting
11. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Although RNA-Sequencing is ... first transcriptome-wide analyses appearing around 2008, RNA-Sequencing has ... RNA measurement. In the last several years, assays ... work with smaller input amounts, process degraded RNA, ... samples). On the bioinformatics side, there have been ...
(Date:7/31/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues, today announced ... will be released on Thursday, August 7, 2014, and ... live webcast at 4:30 p.m. ET that afternoon. Management ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The Kidney Cancer ... of its monthly news magazine, Kidney Cancer News. , ... presence on a website maintained by an international news organization. ... immediate increase in viewers.” , This month’s program highlights news ... tumors analyzed in a recent study. Kidney Cancer News ...
(Date:7/31/2014)... Sales Horizons, a leader in sales training, ... course – Mastering the Complex Sale – ... from proven sales training programs used by thousands of ... online sales training course is available to every salesperson ... with customers, like technical support, engineers, clinical support, and ...
Breaking Biology Technology:The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3
... PARK, N.C. and MIAMI, Oct. 13 The Alpha-1 ... grants to study how genetic variations in the alpha-1 ... in people with AAT deficiency. The inherited condition causes ... whether AAT infusion therapy -- known as augmentation therapy ...
... , CHICAGO, Oct. 13 Advanced Life Sciences ... company engaged in the discovery, development and commercialization ... infection, cancer and respiratory diseases, today announced that ... held October 28-29th in San Francisco. , (Logo: ...
... LONDON, October 13 Systagenix Wound Management ... Board, consisting of,a group of multi-disciplinary and highly respected ... which will be led by,Systagenix,s newly appointed Medical Director, ... major specialist organisations and thought leaders in the,wound care ...
Cached Biology Technology:The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 2The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 3The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 4Advanced Life Sciences to Present at 8th Annual BIO Investor Forum 2Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 2Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 3Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 4Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 5Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 6
(Date:7/30/2014)... Chown has been awarded the Scientific Committee on ... Antarctic Research. , SCAR, an inter-disciplinary international science ... scientific research in the Antarctic region, and on ... Earth system. The organisation also provides scientific advice ... for governing the region. , The medal is ...
(Date:7/30/2014)... into a multitude of cells types. Researchers would like to ... of mature cells that make up the organs and other ... be long chains of sugars that dangle from proteins on ... of California, San Diego, has created synthetic molecules that can ... easily manipulated to direct the process, they report in the ...
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2
... Researchers studying a type of cell found in the trillions ... how it responds to brain injury and disease such as ... trigger the processes that underlie how astrocyte cells respond to ... humans, are a type of glial cell that comprise one ...
... 25, 2013 , , , WHEN:               ... 1, 2013 , , , , LOCATION:       ... , , , SPEAKER:        , , , ... Augmented reality (AR) is here to ...
... of regular aerial surveys and genetics data collected by a ... the central Gulf of Maine as a mating ground for ... online in the journal Endangered Species Research . ... one of the most endangered marine mammal species in the ...
Cached Biology News:Key target responsible for triggering detrimental effects in brain trauma identified 2The (Augmented) Reality of the Situation: Emerging Trends and Issues 2The (Augmented) Reality of the Situation: Emerging Trends and Issues 3Are North Atlantic right whales mating in the Gulf of Maine? 2Are North Atlantic right whales mating in the Gulf of Maine? 3
Lingo-1 (K-13)...
... Hematopoietic stem cells (HSC) are well-characterized tissue-specific ... and are responsible for the life-long maintenance ... cells that reside in adult bone marrow ... can also be found in cord blood, ...
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
Biology Products: